SECTION 351 OF THE PUBLIC HEALTH
SERVICE ACT AND 21 CFR 601.2 REQUIRES UFACTURERS OF BIOLOGICAL
PRODUCTS TO SUBMIT APPLICATIONS FOR REVIEW AND APPROVAL TO THE
BUREAU OF BIOLOGICS PRIOR TO MARKETING PRODUCT. FORM FD 3066 IS
USED BY ALL MANUFACTURERS OF BLOOD GROUPING SERA WHEN APPLYING FOR
A LICENSE FOR A NEW PRODUCT OR WHEN UPDATING INFORMATION (CHANGES
IN MANUFACTURING PROCEDURES, LABELING, ETC.) ON AN ALREADY LICENSED
PRODUCT.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.